Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  American Journal of Cardiology

• Publication date

  2003-11-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-9149(03)00828-2PMID 14609620
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.

  2003cited by this paper
• Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.

  2002cited by this paper
• Effects of tadalafil on erectile dysfunction in men with diabetes.

  2002cited by this paper
• Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil.

  2001cited by this paper
• Granulocytic sarcoma presenting as testicular and paratesticular masses in infancy.

  2001cited by this paper
• On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction

  2001cited by this paper
• Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction

  2001cited by this paper
• Erectile dysfunction.

  2000cited by this paper
• Daily IC351 treatment of erectile dysfunction

  2000cited by this paper
• Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function.

  1999cited by this paper
• Cyclic GMP Phosphodiesterase-5: Target of Sildenafil*

  1999cited by this paper
• Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunction

  1998cited by this paper
• The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

  1997cited by this paper
• Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans.

  1990cited by this paper
• Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence.

  1989cited by this paper

• Fabric phase sorptive extraction coupled with UPLC-ESI-MS/MS method for fast and sensitive quantitation of tadalafil in a bioequivalence study

  2022cites this paper
• Dynamic erectile responses of a novel penile organ model utilizing TPEM †

  2021cites this paper
• Pharmacokinetic and Bioequivalence Evaluation of 2 Tadalafil Tablets in Healthy Male Chinese Subjects Under Fasting and Fed Conditions

  2021cites this paper
• Erectile dysfunction and diabetes: A melting pot of circumstances and treatments

  2021cites this paper
• Therapeutic Strategies for Erectile Dysfunction With Emphasis on Recent Approaches in Nanomedicine

  2020cites this paper
• Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs

  2018cites this paper
• Clinical Practice Guidelines for management of Sexual Disorders in Elderly

  2018cites this paper
• Treatment of Erectile Disorder

  2017cites this paper
• Enhanced Dissolution Rate of Tadalafil Nanoparticles Prepared by Sonoprecipitation Technique: Optimization and Physicochemical Investigation

  2017cites this paper
• Chapter 53 – Diabetes Mellitus: Neuropathy

  2016cites this paper
• Chemopreventive Effect of Tadalafil in Cisplatin-Induced Nephrotoxicity in Rats.

  2016cites this paper
• Erectile dysfunction and its management in patients with diabetes mellitus

  2015cites this paper
• Formulation and Evaluation of Floatingtablet of Gliclazide using HPMC and Xanthan Gum

  2015cites this paper
• Pharmaceutical Prospective Process Validation Of Chloroquiune Tablets

  2015cites this paper
• Zaburzenia erekcji w cukrzycy

  2014cites this paper
• A Comprehensive Review of Erectile Dysfunction in Men with Diabetes

  2014cites this paper
• Medical and Surgical Therapy of Erectile Dysfunction

  2014cites this paper
• An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

  2013cites this paper
• Reproductive sequelae of diabetes in male patients.

  2013cites this paper
• Serum High-Sensitivity C-Reactive Protein Levels and Response to 5 mg Tadalafil Once Daily in Patients With Erectile Dysfunction and Diabetes

  2013cites this paper
• Poly(ADP-ribose) polymerase inhibition improves erectile function by activation of nitric oxide/cyclic guanosine monophosphate pathway in diabetic rats.

  2012cites this paper
• New Treatment Options for Erectile Dysfunction in Patients with Diabetes Mellitus

  2012cites this paper
• The effect of soluble guanylate cyclase activators and a nitric oxide releasing PDE 5 inhibitor on cavernosal and anococcygeal smooth muscle function in conditions of nitric oxide deficiency

  2011cites this paper
• Efectividad y satisfacción con el tratamiento en pacientes con disfunción eréctil en España: Estudio EDOS

  2010cites this paper
• Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial.

  2010cites this paper
• [Effectiveness and treatment satisfaction in patients with erectile dysfunction in Spain: EDOS study].

  2010cites this paper
• Sexual Dysfunction After Radical Prostatectomy: Treatment Failure or Treatment Delay?

  2010influential citation
• Erectile dysfunction, cardiovascular diseases and depression: interaction of therapy

  2009cites this paper
• Erectile dysfunction (ED) is a shared sexual concern of couples II: association of female partner characteristics with male partner ED treatment seeking and phosphodiesterase type 5 inhibitor utilization.

  2009cites this paper
• Erectile dysfunction in diabetes mellitus.

  2009cites this paper
• Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G–Dependent Generation of Hydrogen Sulfide

  2009cites this paper
• Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction.

  2008cites this paper
• Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.

  2008cites this paper
• Type 5 Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction and Cardiovascular Disease

  2007cites this paper
• Phosphodiesterases in the CNS: targets for drug development

  2006cites this paper
• JNJ-10280205 and JNJ-10287069: novel PDE5 inhibitors as clinical candidates for erectile dysfunction

  2006cites this paper
• Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.

  2006cites this paper
• Psychological and Interpersonal Correlates in Men with Erectile Dysfunction and their Partners: A Pilot Study of Treatment Outcome with Sildenafil

  2006cites this paper
• Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells.

  2006cites this paper
• Cutaneous Reaction to Drugs Used for Erectile Dysfunction: Case Report and Review of the Literature

  2006cites this paper
• [Sexual activity and the heart].

  2006cites this paper
• Atividade Sexual e Coração Sexual Activity and Heart

  2006cites this paper
• Upda e Sexual Activity and Heart

  2006cites this paper
• CHAPTER 24 – Male Sexual Function

  2006cites this paper
• Nitric oxide and penile erectile function.

  2005cites this paper
• The efficacy and safety of PDE5 inhibitors.

  2005cites this paper
• Tadalafil-associated anterior ischaemic optic neuropathy

  2005cites this paper
• Aetiology and Management of Male Erectile Dysfunction and Female Sexual Dysfunction in Patients with Cardiovascular Disease

  2005cites this paper
• Assessment, diagnosis, and investigation of erectile dysfunction.

  2005cites this paper
• Effect of Tadalafil on Cytochrome P450 3A4–mediated Clearance: Studies in Vitro and in Vivo

  2005cites this paper
• The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction

  2005cites this paper
• Erectile dysfunction: clinical guidelines (2).

  2004cites this paper
• Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia.

  2004cites this paper
• Review Articles Erectile Dysfunction: Clinical Guidelines (2)

  2004cites this paper
• Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction

  2004cites this paper
• Epidemiological Studies Reporting Prevalence of ED

  2004cites this paper
• ffect of tadalafil on cytochrome P 450 A 4 – mediated clearance : Studies in vitro nd in vivo

  2004cites this paper
• Erectile Dysfunction in Diabetic Patients

  2004cites this paper
• The use of phosphodiesterase type 5 inhibitors for erectile dysfunction.

  2004cites this paper
• Neurologic erectile dysfunction

  2004cites this paper
• Pharmacotherapy of Sexual Dysfunctions : Current Status

  2004cites this paper
• Tadalafil in the treatment of erectile dysfunction

  2003cites this paper
• PDE-5 Inhibition and Sexual Response: Pharmacological Mechanisms and Clinical Outcomes

  2002cites this paper